Intradermal administration of lipopolysaccharide in treatment of human cancer

Cancer Immunology Immunotherapy

Volumn 42, Issue 4, 1996, Pages 255-261

  Goto, Shigenori ^a,b   Sakai, Sumitaka ^a   Kera, Jiro ^a   Suma, Yukie ^a   Soma, Gen Ichiro ^a   Takeuchi, Shoshichi ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b Institute of Bioregulation   (Japan)

Author keywords

cytokine; immunotherapy; lipopolysaccharide; LPSp; tumor necrosis factor

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FATIGUE; FEMALE; FEVER; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOKINES; ENTEROBACTERIACEAE; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PILOT PROJECTS; UTERINE CERVICAL NEOPLASMS;

EID: 0029899887     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050279     Document Type: Article

References (20)

1. Abe S, Takahashi K, Yamazaki M, Mizuno D (1985) Complete regression of Lewis lung carcinoma by cyclophosphamide in combinaion with immunomodulutors. Jpn J Cancer Res (Gann) 76:626
2. Chiba Y, Inagawa H, Okutomi T, Nishizawa T, Goto S, Soma G-I. Mizuno D (1994) Antitumor effect with complete regression by lipopolysaccharide (LPSp) purified from Pantoea agglomerans by intradermal administration. Eur Cytokine Netw 5:231
3. D'Andréa A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041
4. Engelhardt R, Mackensen A, Galanos C, Andreesen R (1990) Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Modif 9:480
5. Engelhardt R, Mackensen A, Galanos C (1991) Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51:2524
6. Fong Y, Moldawer LL, Marano M, Wei H, Tatter SB, Clarick RH, Santhanam U, Sherris D, May LT, Sehgal PB, Lowry SF (1989) Endotoxin elicits increased circulating β2-IFN/IL-6 in man. J Immunol 142:2321
7. Galanos C, Westphal L (1984) Isolation and purification of a standardized lipopolysaccharide from Salmonella abortus equi. In: Homma JY, Kanegasak S, Luderitz O, Shiba T. Westphal O (eds) Bacterial endotoxin chemical, biological and clinical aspects. Weinhein, Basel, p 409
8. Inagawa H, Nishizawa T, Tsukioka D, Suda T, Chiba Y, Okutomi T, Morikawa A, Soma G-I, Mizuno D (1992) Homeostasis as regulated by activated macrophage. II. LPS of plant origin other than wheat flour and their concomitant bacteria. Chem Pharm Bull 40:994
9. Inagawa H, Chiba Y, Nishizawa T, Okutomi T, Soma G-I, Mizuno D (1994) Intradermally administered lipopolysaccharide stimulates TNF-driven inflammation systemically to cure implanted tumour. Eur Cytokine Netw 5:273
10. Kato M, Kakehi R, Soma G-I, Gatanaga T, Mizuno D (1985) Anti-tumor therapy by induction of endogenous tumor necrosis factor. Lancet 2:270
11. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trichieri G, Romagnani S (1993) Natural killer cell stimulatory factor (Interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177:1199
12. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481
13. Nishizawa T, Inagawa H, Oshima H, Okutomi T, Tsukioka D, Iguchi M, Soma G-I, Mizuno D (1992) Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide (LPS) from wheat flour: isolation, purification and some biological activities. Chem Pharm Bull 40:479
14. Noso Y, Becker J, Riveau G, Audibert F, Chedid L (1990) Production and enhanced antitumor activity of tumor necrosis factor in mice treated with cyclophosphamide. Jpn J Cancer Res 81:942
15. Schaadt M, Pfreundschuh M, Lorscheidt G, Peter KM, Steinmetz T, Diehl V (1990) Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. J Biol Response Modif 9:247
16. Shear MJ, Turner FC (1943) Chemical treatment of tumors: isolation of hemorrhagic-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 4:81
17. Soma G-I, Mizuno D (1993) Further developments of the therapy with lipopolysaccharide of a small molecular size on various intractable diseaes. A new version of Coley's toxin. In: Fiers W, Buurman WA (eds) Tumor necrosis factor: molecular and cellular biology and clinical relevance. Karger, Basel, p 203
18. Starnes CO (1992) Coley's toxin in perspective. Nature 357:11
19. Retsas S, Leslie M, Bottomley D (1989) Intralesional tumor necrosis factor combined with interferon gamma in metastatic melanoma. Br Med J 298:1290
20. Tripp CS, Wolf SF, Unanue ER (1993) Interleukin 12 and tumor necrosis factor a are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 90:3725